Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis
Can a strategy of treating patients with drug-sensitive TB for 2 months with combinations which include new drugs or optimised doses of currently available drugs be as effective long term as standard treatment given for 6 months?
What is this study about?
The primary aim is to test the hypothesis that the TRUNCATE-TB management strategy is non-inferior to the standard TB management strategy assessed by the proportion of patients with unsatisfactory outcome at 2 years (96 weeks) after randomisation.
Type of study
Who is funding the study?
When is it taking place?
TRUNCATE-TB was funded in September 2013; the first patient enrolled in March 2018, results expected in 2022.
Where is it taking place?
South East Asia
Who is included?
Adult patients with drug-sensitive pulmonary TB confirmed by GeneXpert.